Immunocore Holdings plc American Depositary Receipt (IMCR)
Compared to Estimates, Immunocore (IMCR) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Immunocore (IMCR) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Wall Street Analysts See a 72.34% Upside in Immunocore (IMCR): Can the Stock Really Move This High?
The consensus price target hints at a 72.3% upside potential for Immunocore (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 65.2% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is it a Good Idea to Invest in Immunocore Stock Right Now?
IMCR revenues surge on robust Kimmtrak sales performance. The momentum is likely to continue in 2025.
Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High?
The mean of analysts' price targets for Immunocore (IMCR) points to an 114.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics
The headline numbers for Immunocore (IMCR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Wall Street Analysts Think Immunocore (IMCR) Could Surge 107.45%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 107.5% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last?
Immunocore (IMCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Immunocore: A Commercial Biotech Nearing Its Pivotal Break-Even Point
Immunocore Holdings focuses on immunotherapy for oncology, with tebentafusp approved for metastatic uveal melanoma and brenetafusp in advanced trials. IMCR's strong balance sheet, with over $800 million in liquid assets, positions them well for future R&D or even a potential acquisition. Growth of tebentafusp sales has slowed, increasing reliance on new projects like brenetafusp, which carries inherent biotech industry risks.
Immunocore Holdings plc (IMCR) Q4 2024 Earnings Call Transcript
Immunocore Holdings plc (NASDAQ:IMCR ) Q4 2024 Earnings Conference Call February 26, 2024 8:00 AM ET Company Participants Clayton Robertson - Head, IR Bahija Jallal - CEO Travis Coy - CFO and Head, Corporate Development Ralph Torbay - Head, Commercial David Berman - Head, R&D Conference Call Participants Michael Yee - Jefferies Jessica Fye - JPMorgan Tyler Van Buren - TD Cowen Eric Schmidt - Cantor Fitzgerald Justin Zelin - BTIG Jonathan Chang - Leerink Partners Ethan Markowski - Needham & Company Peter Lawson - Barclays Patrick Trucchio - H.C. Wainwright Rajan Sharma - Goldman Sachs David Dai - UBS Jeff Jones - Oppenheimer Operator Greetings and welcome to the Immunocore Conference Call and Webcast.
Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store?
IMCR's fourth-quarter 2024 earnings are likely to have gained from higher sales of its sole marketed product, Kimmtrak.
Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 113.1% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
